[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Mutua de Terrassa\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":216},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,53,81,114,139,169,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100641844","eus-guided-gallbladder-drainage-versus-conservative-management-in-patients-unfit-for-surgery-after-a-biliary-event-without-cholecystitis-drecon-study-100641844",false,"NCT07655778","EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study","Multicenter Comparative Clinical Trial: EUS-Guided Gallbladder Drainage Versus Conservative Management in Patients Unfit for Surgery After a Biliary Event Without Cholecystitis. DRECON Study: (DRainage, Endoscopic Ultrasound, CONservative)","DRECON","Inclusion Criteria:\n\n* Patients ≥ 18 years of age\n* Patients who have experienced a benign biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis) and are candidates for elective cholecystectomy\n* Patients deemed unfuit for surgery (age ≥ 80 years, ASA score ≥ 3, Charlson Comorbidity Index ≥ 5) or who voluntarily refuse surgery\n* Diagnosis of lithogenic\u002Flithiasic material in the gallbladder by imaging (biliary sludge, microlithiasis, and\u002For cholelithiasis)\n* Signed informed consent\n\nExclusion Criteria:\n\n* No signed informed consent\n* Prior cholecystectomy\n* Biliary event secondary to malignant etiology\n* Acute cholecystitis diagnosed according to Tokyo 2018 criteria\n* Moderate-to-severe ascites without prior paracentesis\n* Perforated gallbladder\n* Severe coagulopathy (INR \\> 1.5) or thrombocytopenia (platelets \\\u003C 50,000\u002FμL) not correctable\n* Any clinical condition preventing sedation\n* Patient dependent for daily activities (ECOG ≥ 4)","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24],"NA","Cholecystectomy is considered the standard definitive treatment after an acute biliary event (biliary colic, acute pancreatitis, cholangitis, or choledocholithiasis). However, in elderly patients and\u002For those with significant comorbidities, surgery is often not feasible, leaving this population at high risk of biliary event recurrence (approximately 25-31% per year without treatment).\n\nEUS-guided gallbladder drainage (EUS-GBD) using a lumen-apposing metal stent (LAMS) is an established endoscopic technique currently recommended for acute cholecystitis in patients unfit for surgery. It creates an internal fistula between the gallbladder and the adjacent digestive tract, allowing direct endoscopic access for stone clearance (cholecystoscopy). This approach could theoretically prevent biliary event recurrence similarly to cholecystectomy.\n\nThe DRECON study (DRainaige, Endoscopic ultrasound, CONservative) is a multicenter, randomized, comparative clinical trial evaluating whether EUS-GBD with LAMS reduces biliary recurrence at 1 year compared to conservative managment (CM) in patients unfit for surgery after a biliary event without acute cholecystitis who are candidates for elective cholecystectomy.\n\nPrimary hypothesis: EUS-GBD will reduce the risk of biliary event recurrence (biliary colic, acute pancreatitis, cholangitis, choledocholithiasis, or cholecystitis) at 1 year of follow-up compared to conservative management in patients unfit for surgery with gallbladder lithiasis.\n\nEstimated sample: 110 patients (55 per arm). Randomization 1:1 (EUS-GBD vs CM), stratified by centre and prior biliary sphincterotomy. Duration: 24 months recruitment + 12 months follow-up (total 3 years).\n\nParticipating centres: Hospital Universitari Mútua de Terrassa (coordinating centre), Hospital Universitari de Bellvitge, Hospital General de Granollers, Hospital Universitari Parc Taulí de Sabadell, Hospital Universitari de la Santa Creu i Sant Pau, Hospital Clínico Universitario de Valencia, Hospital General Universitario Dr Balmis and Complexo Hospitalario Universitario de A Coruña.",[27,28,29,30,31,32,33,34],"Cholecystectomy","Gallbladder","Endoscopic Ultrasound (EUS)","Cholelithiasis","Acute Pancreatitis Due to Common Bile Duct Calculus","Biliary Colic","Acute Pancreatitis Due to Gallstones","Cholangitis; Choledocholithiasis",[36,37,38,39,40,29],"gallbladder","gallblader drainage","conservative treatment","biliary recurrence","cholecystectomy","NOT_YET_RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-22","ACTUAL",{"date":47,"type":21},"2026-07-01",{"date":49,"type":21},"2029-07-01",{"name":51,"class":52},"Hospital Mutua de Terrassa","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":60,"minAge":18,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},"100613624","cgm-accuracy-in-pregnancy-study-100613624","NCT07269015","CGM Accuracy in Pregnancy Study","Evaluation of the Accuracy of Continuous Glucose Monitoring Systems and Educational Needs in Pregnant Women With Diabetes: A Comparison Between Dexcom One Plus and FreeStyle Libre 2 Plus","Inclusion Criteria:\n\n* Pregnant women with type 1 diabetes, type 2 diabetes, or gestational diabetes, diagnosed before 32 weeks of gestation\n* Age ≥18 years\n* Willingness to wear two CGM systems simultaneously\n* Possession of a smartphone compatible with LibreLink\n* Ability to sign informed consent\n\nExclusion Criteria:\n\n* Comorbidities affecting glucose metabolism\n* Inability to use CGM devices or perform capillary glucose testing","FEMALE",{"count":62,"type":21},66,[24],"Pregnancy in women with diabetes remains a high-risk condition, requiring strict glycemic control due to rapid physiological changes that affect insulin sensitivity. Continuous glucose monitoring (CGM) provides detailed glucose trends, but the accuracy of newer, affordable systems such as Dexcom One Plus and FreeStyle Libre 2 Plus has not been evaluated during pregnancy.\n\nThis prospective interventional study aims to compare the accuracy of these two CGM systems-both worn simultaneously-using capillary glucose as the reference. The study also evaluates educational needs, skills, attitudes, digital competence, lifestyle habits, and patient-reported outcomes among pregnant women with type 1 diabetes (T1D), type 2 diabetes (T2D), and gestational diabetes (GDM).",[66,67],"Pregestational Diabetes","Continuous Glucose Monitoring",[69,70,71],"type 2 diabetes","continuous glucose monitoring","pregnancy","2025-12-04",{"date":74,"type":45},"2025-12-08",{"date":76,"type":21},"2025-12",{"date":78,"type":21},"2027-01",{"name":51,"class":52},1,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":89,"targetDuration":91,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":80},"100598369","study-of-the-natural-history-epidemiological-clinical-diagnostic-and-therapeutic-aspects-of-celiac-disease-and-non-celiac-enteropathies-100598369","NCT07070596","Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-celiac Enteropathies","NATURCEL Registry: Study of the NATURal History, Epidemiological, Clinical, Diagnostic and Therapeutic Aspects of CELiac Disease and Non-celiac Enteropathies","NATURCEL","Inclusion Criteria:\n\n* Individuals under diagnostic evaluation for celiac disease\n\nExclusion Criteria:\n\n* Failure to sign informed consent",{"count":90,"type":21},1000,"10 Years","OBSERVATIONAL","Celiac disease is a chronic immune-mediated enteropathy triggered by gluten intake, which affects the small intestine in genetically susceptible subjects (HLA-DQ2 and\u002For HLA-DQ8). Affecting both children and adults, it is among the most common genetically determined disorders in Western countries. The disease is characterized by clinical manifestations (mainly digestive symptoms and signs of intestinal malabsorption), the presence of specific antibodies (tissue transglutaminase and endomysium) and enteropathy. Currently, the only treatment for celiac disease is a strict gluten-free diet for life.\n\nThe main objective of the NATURCEL registry (Study of the NATURal history, epidemiological, clinical, diagnostic and therapeutic aspects of celiac disease and non-celiac enteropathies) is to collect a wide range of data (epidemiological, clinical, genetic, immunological, etc.) for scientific and translational purposes.\n\nThe registry will include individuals diagnosed with celiac disease or other gluten-related disorders, as well as patients with non-celiac enteropathies evaluated for suspected celiac disease. In the future, the project also aims to establish a biobank-an organized repository of biological samples-to further support scientific and medical research in this field.",[95],"Celiac Disease",[97,98,99,100,101,102,103,104],"Gluten-Related Disorders","Gluten-Free Diet","HLA-DQ2","HLA-DQ8","Tissue Transglutaminase Antibodies","Anti-Endomysial Antibodies","Pediatric and Adult Celiac Disease","TCRγδ+ lymphocytes","RECRUITING","2025-07-08",{"date":108,"type":45},"2025-07-17",{"date":110,"type":45},"2025-06-01",{"date":112,"type":21},"2030-01-01",{"name":51,"class":52},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":60,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":124,"briefSummary":126,"conditions":127,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":80},"100547204","phase-2-transvaginal-human-acellular-dermal-matrix-for-prolapse-treatment-100547204","NCT06404931","Transvaginal Human Acellular Dermal Matrix for Prolapse Treatment","Transvaginal Human Acellular Dermal Matrix and Sacrospinous Fixation for Anterior and Apical Prolapse Treatment in Patients With Hiatal Ballooning or Levator Ani Injury: a Randomized Pilot Trial","Inclusion Criteria:\n\n* Women with symptomatic POP with indication of vaginal surgery.\n* Women with hiatal ballooning or levator ani injury evaluated by 3D pelvic floor ultrasound.\n* Women ≥18 years old.\n* Women wishing to complete a 36-month follow-up.\n* Understand and accept the study procedures and sign the informed consent.\n\nExclusion Criteria:\n\n* Women with previous pelvic floor or prolapse surgery\n* Women with POP grade IV\n* Women with chronic pelvic pain.\n* Not being able to understand the nature of the study and\u002For the procedures to be followed.\n* Not signing the informed consent","100 Years",{"count":123,"type":21},90,[125],"PHASE2","This is a randomised study in which we compare the effectiveness of three different procedures in mending symptomatic anterior and apical prolapse in patients who are candidates to receive surgery.\n\nThey will be randomly assigned in a ratio 1:1:1 to three different groups who will have assigned three different kinds of surgery. In the patients of the first group a classic vaginal hysterectomy with anterior colporrhaphy will be practised. Patients who belong to group two will undergo a vaginal hysterectomy followed by placement of an acellular dermal matrix from cadaveric donors (hADM) for anterior reinforcement and sacrospinous fixation with Anchorsure® device (Neomedic trade mark (TM) International, Spain). Finally, patients from group three will have vaginal hysterectomy followed by sacrospinous fixation with Anchorsure® alone .\n\nPatients will be followed-up at 4 weeks, 6 months, 12 months and annually till 36 months to evaluate relapses and possible complications.",[128,129,130],"Prolapse; Female","Prolapse Genital","Prolapse Uterovaginal","2025-01-15",{"date":133,"type":45},"2025-01-17",{"date":135,"type":45},"2024-07-01",{"date":137,"type":21},"2026-01-01",{"name":51,"class":52},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":146,"minAge":147,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":80},"100573674","virtual-reality-to-reduce-intraoperative-anxiety-in-vasectomies-under-local-anesthesia-100573674","NCT06749353","Virtual Reality to Reduce Intraoperative Anxiety in Vasectomies Under Local Anesthesia","Distraction Manuever to Reduce Intraoperative Anxiety During Vasectomy Procedure Under Local Anesthesia","Inclusion Criteria:\n\n* Male\n* Age between 20 and 90 years old\n* Intervention between 8 am to 12 am.\n* Vasectomy under local anesthesia\n\nExclusion Criteria:\n\n* Language barrier\n* Oncological urological syurgery\n* Surgery time superior to 30 minuts\n* Intellectual disability\n* STAI Trait \\> 70%\n* Intervention after 12 am","MALE","20 Years","90 Years",{"count":150,"type":21},148,[24],"Vasectomy is an elective and ambulatory surgery, typically performed under local anaesthesia. The most common problem that we have found among patients is the anxiety and the apprehension to face the procedure.\n\nVirtual reality (VR), as a novel tool, is relatively underutilized in such medical context. It has been successfully employed across various medical domains, aiding in the training of surgeons, enhancing procedural planning, and offering psychological support to patients.\n\nThis project aims to assess the effectiveness of employing distraction maneuverers, using virtual reality glasses, during the intraoperative period on vasectomy surgery, to mitigate anxiety during the surgical process.\n\nWe want to develop a randomized clinical trial, single-centre study with a control group (conventional procedure) and an intervention group (Virtual reality Glasses). Anxiety was measured using cortisol level through a biomarker saliva test, involving pre and post-procedure samples for each patient. Additionally, we used the State-Trait Anxiety Inventory (STAI) pre and post procedure to evaluate the anxiety and the correlation with the cortisol levels, To evaluate the patient's satisfaction with the used of VR glasses a satisfaction survey was developed. The study protocol has received approval from the ethical committee of our institution.\n\nThe investigators expect to find statistically significant differences in salivary cortisol levels on postoperative samples to prove that VR helps to have a better experience and reduce the intraoperative anxiety.",[154],"Anxiety",[156,157,158,159,160],"anxiety","biomarkers","cortisol","vasectomy","virtual reality","2025-01-08",{"date":163,"type":45},"2025-01-09",{"date":165,"type":21},"2025-01",{"date":167,"type":21},"2026-12",{"name":51,"class":52},{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":80},"100554566","persistent-villous-atrophy-in-celiac-disease-patients-following-an-intentionally-strict-gluten-free-diet-100554566","NCT06500754","Persistent Villous Atrophy in Celiac Disease Patients Following an Intentionally Strict Gluten-free Diet","Study of the Causes and Consequences of Persistent Villous Atrophy Despite an Intentionally Strict Gluten-free Diet in Celiac Disease Patients - Effect of an Ultra-strict Gluten-free Diet on Persistent Villous Atrophy","CADER2","Inclusion Criteria:\n\n* Age at diagnosis 18 years or more.\n* Diagnosis of CD with villous atrophy, positive serology and clinical and serological response to GFD.\n* To be in a GFD for at least 2 years, with good adherence to it.\n* Negative or positive anti-transglutaminase (tTG2) IgA antibodies at low titers (\\\u003C2 times the normal value) at recruitment.\n* Written informed consent.\n\nExclusion Criteria:\n\n* Refractory CD (RCD) type 2 and type 1\n* Other associated intestinal diseases (inflammatory bowel disease, microscopic colitis, other types of enteropathies).\n* Need for treatment with corticosteroids or immunosuppressants.\n* Surgeries or other diseases predisposing to bacterial overgrowth in the small intestine.\n* Pregnancy, lactation.\n* Associated chronic diseases (lung, heart, kidney, liver cirrhosis).\n* Alcoholism or drug addiction.\n* Schizophrenia-type psychiatric diseases, other psychoses, bipolar.","80 Years",{"count":179,"type":21},80,"Celiac disease (CD) is an immune-mediated disease characterized by small intestinal inflammation from gluten ingestion, a group of proteins present in various cereals, including wheat, rye, barley, spelt, and kamut. CD is the most common chronic gastrointestinal disease and one of the most common autoimmune disorders, estimated to affect 0.4-1.7% of the general population. Currently, a strict lifelong gluten-free diet (GFD) is the only available treatment to avoid the inappropriate inflammatory response and prevent the shortening of the villi lining the small intestine (villous atrophy). However, a significant proportion of CD patients, ranging from 4% to 79%, show persistent villous atrophy despite following an intentional GFD. The causative factors and the clinical consequences of persistent villous atrophy in CD patients are not well known yet but might resemble untreated CD long-term complications.\n\nInterestingly, in the precedent study (CADER) persistent villous atrophy was found to be more present in patients diagnosed at an older age (65% of CD patients diagnosed after 30 years of age) than in younger patients. Moreover, unintentional exposure to gluten was found in 70% of the cases. The causative factors of this hypersensitivity to small amounts of gluten present in older patients are unknown. The intestinal microbiota and age-related epigenetic changes may help maintaining the dysregulation of the immune response, causing older patients to be hypersensitive to small amounts of gluten.\n\nThe aim of this study (CADER2) is to identify the immunological and clinical consequences of persistent villous atrophy in CD and study whether changes in the intestinal microbiome and age-related epigenetic modifications may contribute to it. Last, the investigators want to assess if an ultra-strict GFD can be a viable and effective alternative to treat this subset of CD patients. In order to achieve these objectives, the study includes 2 phases: 1) Cross-sectional study to assess the causes and the clinical consequences of persistent villous atrophy in CD patients; and 2) Longitudinal study to evaluate the potential therapeutic effect of an ultra-strict GFD on persistent villous atrophy and its subtle clinical manifestations.\n\nThe investigators hypothesize that persistent villous atrophy in CD patients despite an intentional GFD is associated with chronic low-grade inflammation and increased circulating cytokines in blood, potentially leading to cognitive deficits, fatigue, anxiety, depression, malnutrition, sarcopenia and osteoporosis. The intestinal microbiota and age-related epigenetic changes may help to maintain the dysregulation of the immune response, causing patients to be hypersensitive to small amounts of gluten. This subset of CD patient could highly benefit from an ultra-strict GFD.\n\nTo date, six centers have been recruited: Hospital Universitari Mutua Terrassa (Barcelona), Hospital Clínico San Carlos (Madrid), Hospital Fundación Jiménez Díaz (Madrid), Hospital Universitario de La Princesa (Madrid), Hospital Universitario Ramón y Cajal (Madrid) and Hospital Universitario Virgen Macarena (Sevilla). Digestive, endocrine, nutritional and clinical psychology experts will be involved in the monitoring of the patients. Microbiome analysis will be performed at the Genomics Unit, Microbiota Laboratory (LABMIC) of the IdISSC (Madrid). The methylation studies (age-related epigenetic modifications) will be hired externally.\n\nOverall, the results of this study (CADER2) may help identify new therapeutic strategies as well as improve the management of chronicity and care of CD patients who do not respond to the current treatment. Furthermore, it will contribute to a deeper understanding of the pathophysiological relationships between diet, microbiome, genetics and immunology in CD.",[95,182],"Villous Atrophy of Intestine",[184,185,186,187],"persistent villous atrophy","ultra-strict gluten-free diet","microbiota","epigenetics","2024-07-18",{"date":190,"type":45},"2024-07-19",{"date":192,"type":45},"2022-01-01",{"date":194,"type":21},"2027-01-01",{"name":51,"class":52},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":200,"acronym":201,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":205,"conditions":206,"keywords":4,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":213,"leadSponsor":215,"locationsCount":80},"100509899","detection-program-for-patients-with-primary-biliary-cholangitis-lost-in-the-system-100509899","NCT05919433","Detection Program for Patients With Primary Biliary Cholangitis Lost in the System","RESCAT","Inclusion Criteria:\n\n* Patients with positive AMA and\u002For with positive ANA anti-gp210 or anti-sp100 identified in the computer databases of each of the participating centers.\n* Adults (≥18 years)\n\nExclusion Criteria:\n\n* Patients with Overlap Syndrome (PBC overlap with Autoimmune Hepatitis (AIH))",{"count":204,"type":21},500,"Primary biliary cholangitis (PBC) has been considered a rare disease and its management has been limited by the lack of therapeutic alternatives. PBC is a slowly progressing chronic liver disease characterized by an immune-mediated destruction of the intrahepatic bile ducts, which leads to cholestasis, portal inflammation, and ultimately liver cirrhosis and its associated complications (ascites, portal hypertension, etc), if not treated effectively. Thus, early diagnosis and close management of these patients with PBC is essential. First-line treatment with ursodeoxycholic acid (UDCA) improves liver biochemical parameters, delays histological progression, and increases liver transplant-free survival and overall survival. However, up to 40% of patients are non-responders to UDCA. Obeticholic acid (OCA) is recommended as second-line therapy in combination with UDCA for patients with an inadequate response to UDCA or as monotherapy in cases of UDCA intolerance.\n\nAccording to current clinical guidelines, the diagnosis of PBC includes a combination of elevated alkaline phosphatase (ALP) levels and the presence of anti-mitochondrial antibodies (AMA) (titer \\>1:40) and\u002For anti-nuclear antibodies (ANA) anti-gp210 or anti-sp100. AMA are highly sensitive and specific for PBC and are detected in nearly 95% of PBC patients. A liver biopsy is not necessary unless there is an elevation of ALP without the presence of specific AMA and\u002For anti-gp210 or anti-sp100 ANA or if coexistence with other liver diseases is suspected (autoimmune hepatitis, hepatic steatosis).\n\nThe incidence of PBC has increased in recent years due to an increase in the diagnosis of cases in the initial phases, better awareness in the medical community and the development of more sensitive diagnostic tests. However, up to 31% of patients with PBC are lost without follow-up. The correct identification of patients with PBC is essential so that they can benefit from an adequate treatment and modify disease progression. To date, two studies (one Spanish and one Portuguese) showed that 27% and 45.5% of the patients lost with PBC presented advanced fibrosis, respectively.\n\nThe objective of this study is to identify, through computerized data, patients with PBC who may be lost in the system and evaluate their clinical, analytical and demographic characteristics, and in a second phase, provide access to follow-up in specialized consultations.",[207],"Primary Biliary Cholangitis","2023-06-16",{"date":210,"type":45},"2023-06-26",{"date":212,"type":45},"2023-05-01",{"date":214,"type":21},"2028-12-31",{"name":51,"class":52},""]